C-peptide vs Efinopegdutide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Efinopegdutide |
|---|---|---|
| Category | Pain Management | Weight Management |
| Full Name | Connecting peptide (C-peptide) | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 3020.3 Da | N/A |
| Half-Life | ~20-30 min | Approximately 1 week |
| Amino Acids | 31 | N/A |
| Typical Dose | no approved analgesic dose|research-only | Trial-dependent; weekly SC dosing |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 14 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.